SLC12A2 and kidney disorder: Bumetanide, an FDA-approved diuretic, and nonselective inhibitor of NKCC1 used to treat oedema, cardiac failure, pulmonary congestion, or hepatic and renal disease, such as nephrotic syndrome [14], has also been investigated as a possible treatment targeting NKCC1 upregulation in many neurological diseases [91,92].